Profound Medical Corp. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Profound Medical Corp. on November 28, 2025. The filing serves as a Regulation FD disclosure regarding a significant product development milestone.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate announcement rather than financial performance data.
Material Changes and Events
- Product Launch: The Company announced the launch of its TULSA-AI® Volume Reduction module.
- Event Details: The launch is scheduled for the Radiological Society of North America (RSNA) meeting in Chicago, running from November 30, 2025, through December 4, 2025.
Guidance, Outlook, and Risks
The filing contains no specific financial guidance, outlook, or discussion of risks and contingencies. It strictly reports the timing and location of the upcoming product demonstration. The press release associated with this item is furnished as Exhibit 99.1 and is not deemed "filed" for liability purposes under the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the clinical efficacy and regulatory status of the TULSA-AI® Volume Reduction module.
- Review the full text of the press release (Exhibit 99.1) for specific technical details not included in the 8-K summary.
- Monitor the Company's performance at the RSNA meeting for potential market reception indicators.
- Check subsequent filings for any financial impact or revenue recognition related to this module launch.